COVID-19 — Worldwide/Unknown
Abstract
——–
Background
World Health Organization expert groups recommended mortality trials of 4 repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with coronavirus disease 2019 (COVID-19).
Methods
We randomly assigned inpatients with COVID-19 equally between one of the trial drug regimens that was locally available and open control (up to 5 options, 4 active and the local standard of care). The
…
